1. Khan KS, Wojdyla D, Say L, Gulmezoglu AM, Van Look PF. WHO analysis of causes of maternal death: a systematic review. Lancet. 2006;367(9516):1066-1074.
2. Bellamy L, Casas JP, Hingorani AD, Williams DJ. Pre-eclampsia and risk of cardiovascular disease and cancer in later life: systematic review and meta-analysis. BMJ. 2007;335:974.
3. Mol BW, Roberts CT, Thangaratinam S, Magee LA, de Groot CJ, Hofmeyr GJ. Pre-eclampsia. Lancet. 2016;387:999-1011.
4. Duckitt K, Harrington D. Risk factors for pre-eclampsia at antenatal booking: systematic review of controlled studies. BMJ. 2005;330:565.
5. Henderson JT, Whitlock EP, O'Connor E, Senger CA, Thompson JH, Rowland MG. Low-dose aspirin for prevention of morbidity and mortality from preeclampsia: a systematic evidence review for the U.S. Preventive Services Task Force. Ann Intern Med. 2014;160(10):695-703.
6. Roberts JM, Hubel CA. The two stage model of preeclampsia: variations on the theme. Placenta. 2009;30:32-37.
7. Phupong V, Dejthevaporn T, Tanawattanacharoen S, et al. Predicting the risk of preeclampsia and small for gestational age infants by uterine artery Doppler in low-risk women. Arch Gynecol Obstet. 2003;268(3):158-161.
8. Tannirandorn Y, Charoenvidhya D. Predicting the risk of preeclampsia and small for gestational age infants by uterine artery Doppler in low-risk women. Arch Gynecol Obstet. 2003;268:158-61.
9. Phupong V, Dejthevaporn T. Predicting risks of preeclampsia and small for gestational age infant by uterine artery Doppler. Hypertens Pregnancy. 2008;27:387-395.
10. Sritippayawan S, Phupong V. Risk assessment of preeclampsia in advanced maternal age by uterine arteries Doppler at 17-21 weeks of gestation. J Med Assoc Thai. 2007;90:1281-1286.
11. Kaufmann P, Mayhew TM, Charnock-Jones DS. Aspects of human fetoplacental vasculogenesis and angiogenesis. II. Changes during normal pregnancy. Placenta. 2004;25:114-126.
12. Molvarec A, Fugedi G, Szabo E, etal. Decreased circulating anandamide levels in preeclampsia. Hypertens Res. 2015;38(6):413-418.
13. Nordqvist S, Karehed K, Skoog Svanberg A, Menezes J, Akerud H. Ovarian response is affected by a specific histidine-rich glycoprotein polymorphism: a preliminary study. Reprod Biomed Online. 2015;30(1):74-81.
14. Poon IK, Patel KK, Davis DS, Parish CR, Hulett MD. Histidinerich glycoprotein: the Swiss Army knife of mammalian plasma. Blood. 2011;117(7):2093-2101.
15. Bolin M, Akerud P, Hansson A, Akerud H. Histidine-rich glycoprotein as an early biomarker of preeclampsia. Am J Hypertens. 2011;24(4):496-501.
16. Bolin M, Wikstrom AK, Wiberg-Itzel E, et al. Prediction of preeclampsia by combining serum histidine-rich glycoprotein and uterine artery Doppler. Am J Hypertens. 2012;25(12):1305-1310.
17. Karehed K, Wikstrom AK, Olsson AK, Larsson A, Olovsson M, Akerud H. Fibrinogen and histidine-rich glycoprotein in earlyonset preeclampsia. Acta Obstet Gynecol Scand. 2010;89(1):131-139.
18. Jones AL, Hulett MD, Parish CR. Histidine-rich glycoprotein: a novel adaptor protein in plasma that modulates the immune, vascular and coagulation systems. Immunol Cell Biol. 2005;83(2):106-118.
19. O'Gorman N, Wright D, Poon LC, et al. Accuracy Of Competing-Risks Model in Screening For Preeclampsia By Maternal Factors and Biomarkers at 11-13 Weeks' Gestation. Ultrasound Obstet Gynecol. 2017;49(6):751-755.
20. Kenny LC, Black MA, Poston L, et al. Early pregnancy prediction of preeclampsia in nulliparous women, combining clinical risk and biomarkers The Screening for Pregnancy Endpoints (SCOPE) international cohort study. Hypertension. 2014;64(3):644-652.
21. Aksornphusitaphong A, Phupong V. Combination of serum histidine-rich glycoprotein and uterine artery Doppler to predict preeclampsia. Hypertension Research. 2018; 41(4):275-281.